Physician profile
Eli Eugene Griffin
NPI 1972252310
$493.31
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $39.20 · 2023: $224 · 2024: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $94.50 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $93.65 | 2023 | Xarelto |
| Lilly USA, LLC | $68.61 | 2024 | Mounjaro |
| Abbvie INC. | $61.01 | 2022-2024 | |
| Gilead Sciences, INC. | $42.94 | 2022-2023 | |
| Novo Nordisk INC | $39.56 | 2024 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.96 | 2024 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $20.30 | 2024 | Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.74 | 2023 | Xifaxan |
| Glaxosmithkline, LLC. | $16.04 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eli Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.